Contact information

Clara Redondo

Trial Administrator

BIOGRAPHY

Clara joined the Early Phase Clinical Trials Unit as a Trial Administrator in March 2017. Prior to this she was a Postdoctoral researcher developing inhibitors for specific kinases selected as targets for therapeutic interventions, at the Structural Genomics Consortium in Oxford. Her current role in Clinical Trials mainly focuses on the set-up, activation and follow-up activities, amendment processing and team communications in a varied portfolio of Oncological and Haematological Trials.

Recent publications

Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.

Miranda F. et al, (2016), Cancer Cell, 30, 273 - 289

Novel mitochondrial complex I inhibitors restore glucose-handling abilities of high-fat fed mice.

Martin DSD. et al, (2016), J Mol Endocrinol, 56, 261 - 271

Fenretinide derivatives act as disrupters of interactions of serum retinol binding protein (sRBP) with transthyretin and the sRBP receptor.

Campos-Sandoval JA. et al, (2011), J Med Chem, 54, 4378 - 4387

Cookies on this website